Cerebras
CBRS
$196.20
-1.79%
Cerebras Systems Inc. is an AI company that designs and builds the world's fastest AI infrastructure for training and inference, including the largest semiconductor in the industry and the systems to power, cool, and feed it data. As a challenger to Nvidia in the AI chip market, Cerebras differentiates itself with its wafer-scale engine technology and a software stack that integrates with popular ML frameworks like PyTorch. The company recently went public in May 2026, and its stock has been highly volatile, driven by massive revenue growth, a $25 billion backlog, and partnerships with OpenAI and AWS, but also by concerns over profitability, gross margin guidance, and a rich valuation. The investor narrative centers on whether Cerebras can capitalize on the AI infrastructure boom and achieve sustainable profitability amidst intense competition and high expectations.…
CBRS
Cerebras
$196.20
Related headlines
Investment Opinion: Should I buy CBRS Today?
Rating: Buy (speculative). The thesis is that Cerebras's explosive revenue growth (94% YoY) and massive $25B backlog, coupled with improving margins, justify a premium valuation, but the extreme P/S ratio of 131x requires high execution. Analyst consensus is 'Strong Buy' with an average target of $291.64, implying 38.8% upside. Supporting evidence includes: revenue growth accelerating sequentially, gross margin expansion to 44.56%, positive free cash flow of $145.1M TTM, and a forward P/E of 164.92x that, while high, reflects expected earnings growth. The biggest risks are competitive pressure from Nvidia, potential margin erosion, and valuation compression. This Buy would be downgraded to Hold if revenue growth decelerates below 50% YoY or if gross margins fall below 40%, and upgraded to a more aggressive Buy if the stock pulls back to below $180 while fundamentals remain intact. Overall, the stock is overvalued relative to its history and peers, but the growth potential may justify the premium for high-risk-tolerant investors.
Sign up to view all
CBRS 12-Month Price Forecast
The AI assessment leans bullish due to the company's exceptional growth metrics and improving profitability, which are rare among newly public AI hardware companies. However, the extreme valuation (P/S of 131x) and competitive risks temper confidence. The stance would be upgraded to high confidence if the company reports another quarter of accelerating revenue and expanding margins, while a downgrade to neutral would occur if growth decelerates below 50% or if gross margins fall below 40%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cerebras's 12-month outlook, with a consensus price target around $291.64 and implied upside of +48.6% versus the current price.
Average Target
$291.64
0 analysts
Implied Upside
+48.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$209 - $330
Analyst target range
Cerebras is covered by 11 analysts, with a consensus recommendation of 'Strong Buy' and a mean recommendation score of 1.45 (where 1 is Strong Buy and 5 is Sell). The average target price is $291.64, which implies an upside of 38.8% from the current price of $210.05. The target prices range from a low of $209.00 to a high of $330.00, with the low target nearly at the current price, suggesting some analysts see limited downside. The high target of $330.00 implies a potential upside of 57.1%, reflecting optimism about Cerebras's growth trajectory and market share gains in AI infrastructure. Recent ratings from firms like Rosenblatt, UBS, Wedbush, Morgan Stanley, and Needham have all been positive, with actions such as 'Buy' and 'Overweight', indicating a bullish sentiment among institutional analysts. The relatively wide spread between the low and high targets (a difference of $121.00) suggests high uncertainty about the company's future performance, which is common for newly public, high-growth companies in the AI sector.
Bulls vs Bears: CBRS Investment Factors
Cerebras presents a classic high-risk, high-reward AI growth story. The bull case is anchored by explosive revenue growth, a massive $25B backlog, and strong analyst support, while the bear case centers on an extreme valuation (P/S of 131x vs. industry ~10x) and the competitive threat from Nvidia. Currently, the evidence slightly favors the bulls given the accelerating revenue and improving margins, but the valuation leaves no room for error. The most critical tension is whether Cerebras can convert its backlog and technological edge into sustainable profitability at a scale that justifies its premium multiple, or whether competitive pressures and margin erosion will force a de-rating.
Bullish
- Explosive Revenue Growth: Q1 2026 revenue surged 94.35% YoY to $193.4M, with sequential growth from $171.4M in Q4 2025 and $135.7M in Q3 2025, demonstrating accelerating demand for AI infrastructure.
- Massive $25B Backlog: The company holds a $25 billion backlog, anchored by strategic partnerships with OpenAI and AWS, providing multi-year revenue visibility that supports the high growth expectations.
- Strong Analyst Consensus: With 11 analysts, the consensus is 'Strong Buy' (mean score 1.45), and the average target price of $291.64 implies 38.8% upside from the current price of $210.05.
- Improving Profitability Metrics: Gross margin improved to 44.56% in Q1 2026 from 40.97% in Q4 2025, and operating margin improved from -49.37% in Q4 2024 to -7.77% in Q1 2026, showing a clear path toward breakeven.
Bearish
- Extreme Valuation Premium: The P/S ratio of 131.28x is over 13x the semiconductor industry average of ~10x, implying the market prices in flawless execution and sustained hyper-growth for years.
- Uncertain Profitability: Despite improvements, the company still posted a net loss of $14.0M in Q1 2026, and the forward P/E of 164.92x suggests investors expect a dramatic earnings inflection that may not materialize as quickly.
- High Volatility and Downside Risk: The stock has fallen 45.83% from its 52-week high of $386.34 to $210.05, and its max drawdown of -45.83% highlights the risk of holding a newly public, high-beta AI stock.
- Competitive Pressure from Nvidia: Nvidia dominates the AI chip market with an entrenched ecosystem, and Cerebras's wafer-scale technology, while innovative, faces an uphill battle to gain meaningful market share.
CBRS Technical Analysis
Cerebras has been in a pronounced downtrend since its IPO in May 2026. The stock debuted at $311.07 and quickly fell to a 52-week low of $160.81 on June 25, 2026, before recovering to $210.05 as of September 4, 2026. This places the stock at only 21.4% of its 52-week range (calculated as (210.05 - 160.81) / (386.34 - 160.81)), indicating it is trading near the lower end of its range, which often suggests either a value opportunity or a falling knife. The 1-year price change is not directly available, but the stock has lost approximately 32.5% from its 52-week high of $386.34, reflecting a significant erosion of value since its peak.
Beta
—
—
Max Drawdown
-45.8%
Largest decline past year
52-Week Range
$161-$386
Price range past year
Annual Return
—
Cumulative gain past year
| Period | CBRS Return | S&P 500 |
|---|---|---|
| 1m | -14.7% | -1.4% |
| 3m | -13.4% | +3.3% |
| 6m | — | +15.1% |
| 1y | — | +17.2% |
| ytd | — | +11.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CBRS Fundamental Analysis
Cerebras is experiencing explosive revenue growth, with Q1 2026 revenue of $193.4 million, a 94.35% increase year-over-year (from $99.5 million in Q1 2025). This growth is accelerating, as Q4 2025 revenue was $171.4 million, Q3 2025 was $135.7 million, and Q2 2025 was $103.3 million, showing a consistent sequential increase. The company's gross margin improved to 44.56% in Q1 2026 from 40.97% in Q4 2025, indicating better cost management. However, the company remains unprofitable, with a net loss of $14.0 million in Q1 2026, though this loss narrowed significantly from the $105.7 million loss in Q4 2024. The operating margin was -7.77% in Q1 2026, a substantial improvement from -49.37% in Q4 2024, showing progress toward profitability.
Quarterly Revenue
$193406000.0B
2026-03
Revenue YoY Growth
+94.3%
YoY Comparison
Gross Margin
44.6%
Latest Quarter
Free Cash Flow
$145070500.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CBRS Overvalued?
Given that Cerebras has negative trailing twelve-month net income, the price-to-sales (P/S) ratio is the most appropriate valuation metric. The current P/S ratio is 131.28x, which is extremely high, reflecting the market's high growth expectations. The forward P/E ratio is 164.92x, implying that analysts expect significant earnings growth in the coming year. The gap between the trailing P/S and forward P/E suggests the market is pricing in a dramatic improvement in profitability, which is typical for high-growth AI companies. Compared to the semiconductor industry average P/S ratio of approximately 10x, Cerebras trades at a massive premium, indicating that investors are paying a substantial premium for its growth potential and market position.
PE
758.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
848.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are substantial. The company is unprofitable, with a net loss of $14.0M in Q1 2026, though narrowing from prior quarters. Its debt-to-equity ratio is negative (-0.45), indicating negative equity, which could signal financial fragility, though this is common for high-growth tech firms with accumulated losses. The company's reliance on a few large customers, such as OpenAI and AWS, creates revenue concentration risk; losing one could significantly impact growth. Additionally, the high P/S ratio of 131x means that any slowdown in revenue growth could trigger a sharp valuation correction, as the stock is priced for perfection.
FAQ
The key risks include: 1) Valuation risk: The P/S ratio of 131x leaves no room for error, and any growth slowdown could trigger a severe selloff. 2) Competitive risk: Nvidia's dominance and potential new entrants could erode Cerebras's market share. 3) Financial risk: The company is unprofitable (net loss of $14M in Q1 2026) and has negative equity, though improving. 4) Customer concentration risk: Reliance on OpenAI and AWS for a significant portion of revenue makes the company vulnerable to contract losses. The most severe risk is a combination of these factors leading to a decline to the 52-week low of $160.81, a -23.5% drop from the current price.
The 12-month forecast is bullish, with a base case probability of 45% targeting $250-$291.64, a bull case probability of 30% targeting $291.64-$330, and a bear case probability of 25% targeting $160.81-$209. The most likely scenario is the base case, which assumes continued strong revenue growth and gradual margin improvement. The stock is expected to reach the analyst average target of $291.64, implying a 38.8% upside. However, the wide range of analyst targets ($209-$330) reflects high uncertainty, so investors should be prepared for significant volatility.
CBRS is significantly overvalued relative to its peers, with a P/S ratio of 131.28x compared to the semiconductor industry average of ~10x. This premium reflects the market's expectation of hyper-growth and eventual profitability, as evidenced by the forward P/E of 164.92x. The stock is also trading below its 52-week high of $386.34, but that high was likely unsustainable. Given the extreme valuation, the market is pricing in near-perfect execution, and any disappointment could lead to a sharp de-rating. Therefore, the stock is overvalued on traditional metrics, but the growth potential may justify the premium for some investors.
CBRS is a good buy for investors with a high risk tolerance and a long-term horizon, given its explosive revenue growth (94% YoY) and massive $25B backlog. The analyst consensus is 'Strong Buy' with an average target of $291.64, implying 38.8% upside from the current price of $210.05. However, the stock is extremely volatile (max drawdown -45.83%) and trades at a P/S ratio of 131x, so it is not suitable for conservative investors. A better entry point might be near the 52-week low of $160.81, but the current price offers a reasonable risk/reward if the company executes on its growth plans.
CBRS is better suited for long-term investment (3-5 years) rather than short-term trading, given its high volatility (beta not provided, but price swings are extreme) and the early stage of its growth trajectory. The company is investing heavily in R&D and capacity expansion to capture the AI infrastructure boom, which should play out over several years. Short-term traders may find opportunities in the stock's volatility, but the risk of sharp drawdowns (max -45.83%) is high. For long-term investors, the key is to hold through the volatility and monitor execution on the $25B backlog and path to profitability.